These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21992747)

  • 21. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
    Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
    Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post Hoc analysis of a randomized, double-blind, placebo-controlled trial.
    Aronson S; Van Baelen B; Kavanagh S; Schwalen S
    Drugs Aging; 2009; 26(3):231-9. PubMed ID: 19358618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin degrading enzyme (IDE) genetic variants and risk of Alzheimer's disease: evidence of effect modification by apolipoprotein E (APOE).
    Edland SD; Wavrant-De Vriesé F; Compton D; Smith GE; Ivnik R; Boeve BF; Tangalos EG; Petersen RC
    Neurosci Lett; 2003 Jul; 345(1):21-4. PubMed ID: 12809979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Apolipoprotein E ɛ4 Carrier Status on Cognitive Response to Acetylcholinesterase Inhibitors in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Cheng YC; Huang YC; Liu HC
    Dement Geriatr Cogn Disord; 2018; 45(5-6):335-352. PubMed ID: 30041236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of Alzheimer's Disease With APOE and IL-1α Gene Polymorphisms.
    Yildiz SH; Erdogan MO; Artan S; Solak M; Yaman M; Ozbabalik BD; Terzi ES
    Am J Alzheimers Dis Other Demen; 2015 Dec; 30(8):756-61. PubMed ID: 23038715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study.
    Saumier D; Duong A; Haine D; Garceau D; Sampalis J
    J Nutr Health Aging; 2009 Nov; 13(9):808-12. PubMed ID: 19812871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
    Farlow M; Lane R; Kudaravalli S; He Y
    Pharmacogenomics J; 2004; 4(5):332-5. PubMed ID: 15289797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
    Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
    Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
    Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin-degrading enzyme, apolipoprotein E, and Alzheimer's disease.
    Edland SD
    J Mol Neurosci; 2004; 23(3):213-7. PubMed ID: 15181249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
    Pomara N; Ott BR; Peskind E; Resnick EM
    Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. APOE gene-dependent BOLD responses to a breath-hold across the adult lifespan.
    Rasmussen PM; Aamand R; Weitzberg E; Christiansen M; Østergaard L; Lund TE
    Neuroimage Clin; 2019; 24():101955. PubMed ID: 31408838
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cognitive phenotypes in Alzheimer's disease and genetic variants in ACE and IDE.
    Vardy ER; Brown K; Stopford CL; Thompson JC; Richardson AM; Neary D; Kalsheker N; Morgan K; Mann DM; Snowden JS
    Neurobiol Aging; 2012 Jul; 33(7):1486.e1-2. PubMed ID: 21232820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment.
    Fleisher AS; Sowell BB; Taylor C; Gamst AC; Petersen RC; Thal LJ;
    Neurology; 2007 May; 68(19):1588-95. PubMed ID: 17287448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer's disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil.
    Fullerton T; Binneman B; David W; Delnomdedieu M; Kupiec J; Lockwood P; Mancuso J; Miceli J; Bell J
    Alzheimers Res Ther; 2018 Apr; 10(1):38. PubMed ID: 29622037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Severity-Related Increase and Cognitive Correlates of Serum VEGF Levels in Alzheimer's Disease ApoE4 Carriers.
    Alvarez XA; Alvarez I; Aleixandre M; Linares C; Muresanu D; Winter S; Moessler H
    J Alzheimers Dis; 2018; 63(3):1003-1013. PubMed ID: 29710700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metrifonate treatment of AD: influence of APOE genotype.
    Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
    Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Apolipoprotein E Gene Polymorphisms Affect the Efficacy of Thiazolidinediones for Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Iketani R; Ohno K; Kawasaki Y; Matsumoto K; Yamada H; Kishino S
    Biol Pharm Bull; 2018; 41(7):1017-1023. PubMed ID: 29962398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.